期刊文献+

拉米夫定联合灵芝胶囊治疗慢性乙型肝炎30例临床观察 被引量:7

Treatment of Chronic Hepatitis B by Lamivudine Combined with Lingzhi Capsule:A Clinical Observation of 30 Cases
下载PDF
导出
摘要 目的:观察灵芝胶囊联合拉米夫定治疗慢性乙型肝炎的疗效。方法:将60例患者随机分为治疗组与对照组各30例。治疗组给予口服用灵芝胶囊、联合拉米夫定;对照组口服拉米夫定。疗程均为1年。结果:治疗组在促进HBV—DNA转阴、HBeAg阴转及HBeAg/HBeAb血清转换方面,优于对照组(P<0.05);治疗组能够较早使ALT恢复正常,并且最终复常率明显优于对照组,2组比较,差异有显著性意义(P<0.05);YMDD变异治疗组有1例,对照组有6例,2组比较,差异有显著性意义(P<0.05),提示治疗组联合治疗产生YMDD变异少于对照组。结论:灵芝胶囊与拉米夫定联合应用治疗慢性乙型肝炎有明显的协同作用,可显著改善肝功能、快速抑制HBV—DNA的复制、促使HBeAg的阴转和血清转换,短期疗效优于单用拉米夫定。 Objective:To observe the curative effect of lamivudiae combined with Lingzhi capsule(LC,灵芝胶囊)for chronic hepatitis B(CHB).Methods:60 cases of CHB were allocated to 2 groups(each group 30 cases)randomly.The treatment group was treated by oral use of LC combined with lamisudine and coronal group by lamivudine alone.One year constituted the course of treatment.Results:In treatment group,the promotion of turniag negative HBV-DNA,HBeAg and transfer of H BeAg/Anti-HBe were superior than that of control group(P<0.05);the recovery rate of ALT was earlier in treatment group than that of control group(P<0.05);the variation of YMDD was one case and 6 cases in treatment group and control group respectively(P<0.05).it is indi- cated that the variation of YMDD of treatment group was less than that of control group.Gonclusion:LC combined with lamivudine showed marked synergistic action for CHB,markedly improve liver function,inhibit the replication of HBV-DNA rapidly,promote the turning negative of HBeAg and the transfer of serum,and the short-term curative effect is superior than that of lamivudine,group.
出处 《新中医》 CAS 北大核心 2007年第3期78-79,共2页 New Chinese Medicine
  • 相关文献

参考文献2

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14010
  • 2中华人民共和国卫生部.中药新药临床研究指导原则[S].,1993.79-83,96-99.

共引文献14432

同被引文献91

引证文献7

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部